Dedicate Double-Blind Evaluation of Dapagliflozin on the Incidence of Cardiovascular-Associated Events Trademark Details

This mark is dead with a status of Abandoned-Failure to Respond or Late Response. The last case file activity for this mark occured 11 years ago on Friday, December 14, 2012, according to the United State Patent & Trademark Office
Word Mark Dedicate Double-Blind Evaluation of Dapagliflozin on the Incidence of Cardiovascular-Associated Events
Status Dead 602 — Abandoned-Failure to Respond or Late Response

Current Owner

Bristol-Myers Squibb Company of New York, NY

View all trademarks for Bristol-Myers Squibb Company
Other Trademarks for Bristol-Myers Squibb Company
Serial Number 85525589
Status Date Friday, December 14, 2012
Filing Date Friday, December 14, 2012
Attorney Marilyn F. Kelly

Correspondent

MARILYN F. KELLY
BRISTOL-MYERS SQUIBB COMPANY
345 PARK AVE
NEW YORK, NY 10154-0004

Case File Statements

Goods & Services Medical and scientific research, namely, conducting clinical trials and clinical studies relating to pharmaceutical preparations for human use

Classifications

International Class Codes
042 — Class 42 includes mainly services provided by persons, individually or collectively, in relation to the theoretical and practical aspects of complex fields of activities; such services are provided by members of professions such as chemists, physicists, engineers, computer programmers, etc.
U.S. Class Codes 100, 101
Status 6 — Active
Status Date Monday, January 30, 2012
Primary Code 042

You must be signed in to print.

Once signed in, look for the PDF button.